Fosamprenavir

The ritonavir-boosted protease inhibitors studied were lopinavir, atazanavir, darunavir and fosamprenavir; the NNRTI was efavirenz and the NRTI was tenofovir.

Significant interactions were observed between telaprevir and boosted-lopinavir, darunavir and fosamprenavir, such that telaprevir-based combination therapy is not currently being evaluated for people taking these HIV medicines.

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed ... ❋ Editors (2010)

There is no reason to suspect decreased susceptibility, thus the dose of LPV / r is higher than currently recommended in a patient concomitantly on fosamprenavir (FPV). ❋ Unknown (2009)

Information includes initial recommendations for the new PIs lopinavir / ritonavir, atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs. ❋ Unknown (2009)

INTELENCE should not be coadministered with the following ARVs: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg bid), protease inhibitors administered without low-dose ritonavir, and other NNRTIs

-- INTELENCE should not be co-administered with the following ARVs: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg bid), protease inhibitors administered without ritonavir, and other NNRTIs. ❋ Unknown (2009)

The following medicines may need changes when taken with Kaletra: birth control pills that contain estrogen ( "the pill"), birth control (contraceptive) patches, atorvastatin (Lipitor®), rosuvastatin (Crestor®), efavirenz (Atripla® and Sustiva®), nevirapine (Viramune®), amprenavir (Agenerase®), fosamprenavir (Lexiva®), nelfinavir ❋ Unknown (2010)